The main molecular mechanisms of GLP-1RA in obesity reduction include the increased production of insulin by the cAMP/PKA pathway in pancreatic -cells, along with an augmented translocation of GLUT-4 in the cellular membrane for improved glucose homeostasis, and energy expenditure by lipolytic cycle stimulation
Although the exact pathophysiological mechanism remains elusive, this case contributes to the growing body of literature suggesting that semaglutide might induce liver injury
While this approach works well at first, it has a high hidden cost: tracking can become fragmented, making early metabolic wins hard to see
Among these, glucagon-like peptide-1 receptor agonists (GLP1RAs) have attracted particular attention for their profound effects on body weight, glycemic control, and cardiovascular outcomes [4,5] , which extend beyond metabolic effects [4] , alongside emerging evidence of liver-specific benefits [5,6]
The phase I trial (Clinical trials ID: NCT02113020) was undertaken in 2014
